Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma: Final Results From the MCRN-003/MYX.1 Single Arm Phase II Trial
Am. J. Hematol 2021 Mar 01;[EPub Ahead of Print], CP Venner, R LeBlanc, I Sandhu, D White, AR Belch, DE Reece, C Chen, S Dolan, M Lalancette, M Louzada, A Kew, A McCurdy, B Monteith, T Reiman, G McDonald, M Sherry, E Gul, BE Chen, AE HayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.